

. . . .

Ì

New Hampshire AIDS Drug Assistance Program

Prior Authorization Drug Approval Form

buprenorphine/naloxone and buprenorphine (oral)

DATE OF MEDICATION REQUEST: / /

| SE | CTION I: PATIENT INFORMATION AND MEDICATION | REQUESTE | D | | | | | | | | | | |
|---|---|-------------|----------|------|-------|-------|------|------|---|------------|------|------------------|--|
| LAS | ST NAME: | FIRST NAME: | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| ME | DICAID ID NUMBER: | DATE O | | 1: | | | | | | . <u> </u> | | | |
| | | |] – [| | | – | | | | | | | |
| GEI | NDER: Male Female | | J L | | | 1 | L | | 1 | <u> </u> | | | |
| Dru | ıg Name: | | | 9 | Stren | gth: | | | | | | | |
| Dos | sing Directions: | | | | .eng | th of | Ther | apy: | | | | | |
| | | | | | | | | | | | | | |
| SE | CTION II: PRESCRIBER INFORMATION | | | | | | | | | | | | |
| LAS | | FIRST N | AME: | | | | | 1 | | , | | | |
| | | | | | | | | | | | | | |
| SPE | CIALTY: | NPI NUN | /IBER: | | | | | | | , | | | |
| | | | | | | | | | | | | | |
| PH | ONE NUMBER: | FAX NUI | MBER: | | | | | _ | | | | | |
| | | | | - | | | | _ | | | | | |
| SE | CTION III: CLINICAL HISTORY: | | | | | | | | | | | | |
| 1. | Is this request for treatment of opiate use disorder? | | | | | | | | | | es 🗌 | No | |
| | If <i>no</i> , what is the diagnosis for usage? | | | | | | | | | | | | |
| 2. | Is the patient receiving addiction counseling? | | | | | | | | | | |] No | |
| 3. | Has a substance use disorder assessment been performed? | | | | | | | | | | | No | |
| 4. | Is the patient 16 years of age or older? | | | | | | | | | | |] No | |
| 5. | Do you attest that the NH Prescription Drug Monitoring Program has been reviewed in the last 60 days? | | | | | | | | | | es 🗌 |] No | |
| 6. If approved, will the patient require concurrent opioid medication or methadone therapy? | | | | | | | | | | | es 🗌 |] No | |
| (Fo | rm continued on next page.) | | | | | | | | | | | | |
| © 2 | one: 1-800-424-7901 Fax: 1-800-424-7984 2021–2025 Prime Therapeutics Management LLC, a Prime ⁻ view Date: 06/05/2025 | Therapeutic | s LLC co | ompa | ny | | | | | Pr | | e Ics™ | |



New Hampshire AIDS Drug Assistance Program Prior Authorization Drug Approval Form

buprenorphine/naloxone and buprenorphine (oral)

| PATIENT LAST NAME: | | | | | | | | | PATIENT FIRST NAME: | | | | | | | | | | | | | | | |
|---|---|--|--|--|--|--|--|--|---------------------|--|--|--|--------|------------|--|--|--|--|--|--|--|--|--|--|
| | | | | | | | | | | | | | | | | | | | | | | | | |
| SECTION III: CLINICAL HISTORY (Continued) | | | | | | | | | | | | | | | | | | | | | | | | |
| 7. | Is the patient pregnant or lactating? | | | | | | | | | | | | | 🗌 Yes 🗌 No | | | | | | | | | | |
| 8. | <i>For buprenorphine single agent request ONLY</i> : Is there documented allergic reaction to buprenorphine/naloxone combination product? Please provide type of reaction and date: | | | | | | | | | | | | Yes No | | | | | | | | | | | |

9. Provide any additional information that would help in the decision-making process. If additional space is needed, please use a separate sheet.

I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

PRESCRIBER'S SIGNATURE: _____

